| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1191/135248505ms1277oa The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkersDepartment of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK, a.petzold{at}ion.ucl.ac.uk
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK
Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK This study investigated whether the new Global Multiple Sclerosis Severity Scale (MSSS) correlated with cerebrospinal fluid biomarkers for axonal and glial pathology. The MSSS correlated with the phosphorylated neurofilament heavy chain (NfH-SMI35, R=0.44, P=0.016). The degree of neurofilament phosphorylation (ratio NfH-SMI34 to NfH-SMI35) was 8-fold higher in severely (median MSSS 6.5) versus mildly (MSSS 3.2) disabled patients (7.3 versus 0.9, P=0.03). The MSSS may provide a statistically powerful tool for comparing overall disease severity and be useful for validating the biomarker concept in MS.
Key Words: biomarker MSSS multiple sclerosis
|